REGISTER
WCLC 2026: Five Shanghai East Hospital Studies Span EGFR-ADC, KRAS G12D, ES-SCLC
At WCLC 2026, Shanghai East Hospital reports five lung cancer studies led by Prof. Caicun Zhou: GREAT Phase III (n=1024) showed segmentectomy improved re-expansion and cut complications vs lobectomy in GGO early lung cancer; SYS6010 (EGFR-ADC) + enlonstobart Phase II (n=133) was safe in AGA-negative NSCLC; QLC1101 (oral KRAS G12D inhibitor) Phase I (n=52) had no DLTs; HARMONi-2 OS data (ivonescimab vs pembrolizumab) pending; QLC5508 + QL1706/QL2107 Phase II in ES-SCLC hit 100% ORR/DCR

From September 12 to 15, 2026, the 27th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), will convene in Seoul, Korea, gathering the global lung cancer community around the latest advances in diagnosis, treatment, and translational research. Among the conference highlights, a team led by Prof. Caicun Zhou at Tongji University-affiliated Shanghai East Hospital has five studies accepted for Oral and Mini Oral presentations, spanning surgical optimization in ground-glass opacity (GGO)-type early lung cancer, combination therapies for advanced non-small cell lung cancer (NSCLC), KRAS G12D-targeted therapy, and first-line options for extensive-stage small cell lung cancer (ES-SCLC). MedJ has compiled the research highlights below.

Oral Presentations

OA08.02 — Perioperative Outcomes of the GREAT Phase III Trial of Segmentectomy Versus Lobectomy for GGO-Containing Early Lung Cancer

Presenter: Prof. Y. Chen

https://pubmed.ncbi.nlm.nih.gov/36741022

GREAT is a prospective, open-label, randomized Phase III trial comparing minimally-invasive segmentectomy with lobectomy in GGO-containing early lung cancer. The study enrolled patients with peripheral GGO-associated tumors (consolidation tumor diameter >0.5 to ≤3 cm; solid component >0.5 to ≤2 cm), randomized 1:1 to lobectomy or segmentectomy (resection extent less than half of the corresponding lobe). A concurrent wedge resection for synchronous multifocal GGO lesions was permitted. The primary endpoint is 5-year relapse-free survival (RFS); the current analysis focused on pre-specified secondary endpoints including residual lung re-expansion, postoperative day 1 (POD1) pulmonary function, complications, and re-intervention.

Between June 2021 and January 2025, 1024 patients were randomized. Concurrent wedge resection rates were comparable between arms (10.2% vs 8.6%; P=0.391). The segmentectomy arm achieved significantly better residual lung re-expansion (P=0.008) and smaller declines in POD1 forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1; both P<0.001). Any-grade complications (7.2% vs 10.9%; P=0.039), Common Terminology Criteria for Adverse Events (CTCAE) ≥2 complications (3.1% vs 5.9%; P=0.035), and overall re-intervention rates (1.0% vs 2.7%; P=0.037) were all lower with segmentectomy, with greater advantages in the wedge-resection subgroup. The authors concluded that minimally-invasive segmentectomy, compared with lobectomy, improved residual lung re-expansion and early pulmonary function preservation while reducing postoperative complications and re-intervention — perioperative benefits that may be especially meaningful for patients requiring concurrent wedge resection of multifocal GGO lesions.

OA10.02 — Phase II Study of SYS6010 Plus Enlonstobart in Actionable Genomic Alteration (AGA)-Negative Advanced NSCLC

Presenter: Prof. Wei Li

https://clinicaltrials.gov/study/NCT07633873

This randomized Phase II cohort within a multicenter, open-label Phase I/II trial evaluated the epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) SYS6010 in combination with the PD-1 inhibitor enlonstobart as first-line therapy in AGA-negative advanced NSCLC. Patients were randomized 1:1 to Arm A (SYS6010 4.2 mg/kg + enlonstobart 360 mg every 3 weeks) or Arm B (SYS6010 3.6 mg/kg + enlonstobart 240 mg every 2 weeks), stratified by programmed death-ligand 1 (PD-L1) tumor proportion score (TPS). Primary endpoints were safety and investigator-assessed objective response rate (ORR).

As of March 17, 2026, 133 patients had been enrolled (median age 64.0 years; 83.5% male), with adenocarcinoma accounting for 60.2% and squamous carcinoma 27.8% of cases. Median follow-up was 6.4 months. Treatment-related adverse events (TRAEs) of ≥3 grade occurred in 41.9% (Arm A) and 37.3% (Arm B), with no TRAE-related deaths. The most common ≥3 TRAEs were neutropenia (25.7% vs 16.9%) and leukopenia (10.8% vs 6.8%). Interstitial lung disease (ILD)/pneumonitis occurred in 7 patients, mostly grade 1-2. Median duration of response had not been reached; progression-free survival (PFS) and overall survival (OS) data were immature. Both schedules demonstrated manageable safety and encouraging efficacy, with notable activity in PD-L1-positive patients (particularly TPS ≥50%) and across squamous and non-squamous histologies.

OA12.02 — Safety and Efficacy of QLC1101 in Advanced NSCLC Harboring KRAS G12D Mutation

Presenter: Prof. Anwen Xiong

https://clinicaltrials.gov/study/NCT06403735

This first-in-human Phase I trial evaluated QLC1101, an oral highly selective KRAS G12D inhibitor, in patients with KRAS G12D-mutated advanced NSCLC. During dose escalation, QLC1101 was administered at 100-1600 mg twice daily (BID) in 21-day cycles. The primary endpoint was the recommended Phase II dose (RP2D); secondary endpoints were safety and preliminary efficacy by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

As of February 12, 2026, 52 patients had been enrolled (48.1% male; 15.4% with brain metastases). No dose-limiting toxicities (DLTs) occurred; 82.7% of patients experienced TRAEs, 9.6% had ≥3 TRAEs, and none led to treatment discontinuation or death. The most common TRAEs were diarrhea (65.4%), vomiting (61.5%), nausea (40.4%), and decreased appetite (25%), mostly grade 1-2. At the RP2D of 1200 mg BID post-meal (31 patients), only 2 (6.5%) experienced ≥3 TRAEs.

Across all dose levels, 42 evaluable patients showed an ORR of 26.2%, disease control rate (DCR) of 78.6%, median PFS of 7.2 months, and 9-month PFS rate of 37.4%. At the RP2D specifically, 22 evaluable patients showed an ORR of 22.7%, DCR of 90.9%, median PFS not reached, and a 9-month PFS rate of 67.1%. The authors concluded that QLC1101 was well tolerated and showed preliminary antitumor activity in KRAS G12D-mutated advanced NSCLC, supporting further development; enrollment in additional solid tumors including pancreatic ductal adenocarcinoma is ongoing.

OA14.01 — Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-Line Treatment for PD-L1-Positive NSCLC

Presenter: Prof. Caicun Zhou

https://clinicaltrials.gov/study/NCT05499390(+ Lancet 2025)

Overall survival results from the HARMONi-2 trial are awaited; data will be presented at the meeting.

Mini Oral Presentation

MO15.02 — A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Presenter: Prof. X. Chen

https://clinicaltrials.gov/study/NCT07802821

This multicenter, open-label, single-arm Phase II trial evaluated the B7-H3 ADC QLC5508 combined with either iparomlimab-torvorvelimab (QL1706, a PD-1/CTLA-4 bispecific antibody) or the pembrolizumab biosimilar QL2107 as first-line therapy in ES-SCLC. Cohort 1 received QLC5508 2.4 mg/kg + QL1706 5 mg/kg; Cohort 2 received QLC5508 2.4 mg/kg + QL2107 200 mg. The primary endpoint was ORR by RECIST 1.1.

As of April 14, 2026, Cohort 1 and Cohort 2 had enrolled 16 and 36 patients respectively, with 10 patients each included in the evaluable analysis. All evaluable patients achieved partial response (PR); both cohorts showed ORR and DCR of 100%. Treatment-emergent adverse events (TEAEs) occurred in 100% (≥3 grade: 40.0%) in Cohort 1 and 82.1% (≥3 grade: 35.7%) in Cohort 2. QLC5508-related ≥3 AEs occurred in 40.0% and 32.1% of patients respectively. The most common QLC5508-related AEs were alanine aminotransferase (ALT) elevation, hypoalbuminemia, and anemia. The authors concluded that QLC5508 combined with QL1706 or QL2107 as first-line therapy showed encouraging antitumor activity and manageable safety in ES-SCLC, suggesting that B7-H3 ADC plus PD-1 or PD-1/CTLA-4 regimens merit further investigation as potential treatment options for this aggressive disease.

0
0
Loading